Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor
Article Tile: Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor
Uveal melanoma (UM) originates in the uvea and is the most common form of adult intraocular cancer. Primary UM is treated by ocular radiation or by surgical removal of the eye. Once UM metastasizes, patient survival is poor with the limited benefit of therapeutic options. The authors of this study evaluated the efficacy of ACY-1215, a histone deacetylase inhibitor, to slow the growth of primary UM and potentially metastatic UM (MUM) in the liver.
The authors found a significant dose-dependent reduction in clones of the primary ocular UM cells using ACY-1215. Using in vitro MUM cell lines, a dose-dependent reduction of cell survival was found using ACY-1215. Similarly, a significant attenuation of MUM xenografts in zebrafish larvae was noted. These cells were observed to arrest in the S phase after 24 hours of treatment and significant apoptosis was initiated in a time and dose-dependent manner. The anti-cancer effects of ACY-1215 were linked to the attenuation of the microphthalmia-associated transcription factor signalling pathway.
The results of this study demonstrate the potential of ACY-1215 as a treatment option for metastatic UM.
Sundaramurthi H, García-Mulero S, Tonelotto V, Slater K, Marcone S, Piulats JM, Watson RW, Tobin DJ, Jensen LD, Kennedy BN. Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor. Cancers. 2022; 14(3):782. https://doi.org/10.3390/cancers14030782
Date Published: February 3rd, 2022
Summary by: Sarah Yeo